|
Cerebrovascular accident
|
0.290 |
Biomarker
|
group |
BEFREE |
We evaluated whether copeptin and S100b protein (PS100b) assessment, alone or in combination, could rule out stroke in patients visiting EDs for dizziness.
|
31387626 |
2019 |
|
Cerebrovascular accident
|
0.290 |
Biomarker
|
group |
BEFREE |
This review addresses this novel scenario, presenting data indicating that S100B levels and/or distribution in the nervous tissue of patients and/or experimental models of different neural disorders, for which the protein is used as a biomarker, are directly related to the progress of the disease: acute brain injury (ischemic/hemorrhagic stroke, traumatic injury), neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis), congenital/perinatal disorders (Down syndrome, spinocerebellar ataxia-1), psychiatric disorders (schizophrenia, mood disorders), inflammatory bowel disease.
|
30144068 |
2019 |
|
Cerebrovascular accident
|
0.290 |
Biomarker
|
group |
BEFREE |
Atrial fibrillation, leukocyte count, CRP, NSA, uPA, IL-6 and S100B showed an independent impact on the functional status on the 30<sup>th</sup> day of stroke.
|
31356182 |
2019 |
|
Cerebrovascular accident
|
0.290 |
Biomarker
|
group |
BEFREE |
Our findings demonstrate that S100B promotes microglia M1 polarization to aggravate cerebral ischemia, and provide a better understanding on the therapeutic effects of S100B and/or its antagonist/neutralization antibody in stroke.
|
30229393 |
2018 |
|
Cerebrovascular accident
|
0.290 |
Biomarker
|
group |
BEFREE |
However, the clinical usefulness of S-100β biomarker in the diagnosis and prognosis of stroke has a limitation due to its low discriminating ability in stroke diagnosis and prognosis.
|
29792379 |
2018 |
|
Cerebrovascular accident
|
0.290 |
Biomarker
|
group |
BEFREE |
Serum hs-cTnT was measured 6 and 24 hours after stroke, whereas S100B, high-sensitivity C-reactive protein (hsCRP), soluble CD40 ligand, tissue plasminogen activator (tPA), monocyte chemoattractant protein-1 (MCP-1), and P-selectin were measured 6 and 72 hours after stroke.
|
29249591 |
2018 |
|
Cerebrovascular accident
|
0.290 |
Biomarker
|
group |
LHGDN |
S-100 protein blood plasma concentration assessed on the 1st day after the ischemic stroke is the parameter presenting the highest diagnostic utility and its value above 0.6 ng/ml was obtained only in patients with severe stroke.
|
17984926 |
2007 |
|
Cerebrovascular accident
|
0.290 |
Biomarker
|
group |
BEFREE |
Serum S100 and plasma DNA were increased in 126 (p<0.0010) and 36 (p=0.21) stroke patients respectively vs. controls.
|
17027951 |
2007 |
|
Cerebrovascular accident
|
0.290 |
ModifyingMutation
|
group |
RGD |
Our results showed that single measurements of serum S100B 48 h after PIT stroke would serve as an early and simple surrogate marker for long-term evaluation of histological and neurological outcomes in PIT stroke rat models.
|
17706250 |
2007 |
|
Cerebrovascular accident
|
0.290 |
Biomarker
|
group |
BEFREE |
These biochemical markers, myelin basic protein (MBP), neuron-specific enolase (NSE), S100beta, and soluble thrombomodulin, were studied for an association with initial stroke severity, infarct volume, and functional outcome.
|
16960091 |
2006 |